unknown
Stage
2023
Founded
1
Investors
About
Develops next-generation bispecific and multispecific antibody-drug conjugates (ADCs) for oncology. Uses protein engineering, synthetic biology, high-throughput phenotypic screening and AI-driven discovery to design and optimize cancer therapeutics.
Explore Valink Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.